These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

396 related items for PubMed ID: 35461050

  • 1. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice.
    Steeghs EMP, Groen HJM, Schuuring E, Aarts MJ, Damhuis RAM, Voorham QJM, PATH consortium, Ligtenberg MJL, Grünberg K.
    Lung Cancer; 2022 May; 167():87-97. PubMed ID: 35461050
    [Abstract] [Full Text] [Related]

  • 2. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.
    Aggarwal A, Sharma S, Brar Z, Kumar V, Kumar A, Katara R, Mohanty SK.
    Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714
    [Abstract] [Full Text] [Related]

  • 3. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC, Lai GGY, Tan GS, Poon SY, Doble B, Lim TH, Aung ZW, Takano A, Tan WL, Ang MK, Tan BS, Devanand A, Too CW, Gogna A, Ong BH, Koh TPT, Kanesvaran R, Ng QS, Jain A, Rajasekaran T, Lim AST, Lim WT, Toh CK, Tan EH, Lim TKH, Tan DSW.
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [Abstract] [Full Text] [Related]

  • 4. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ, Haslam A, Gill J, Prasad V.
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [Abstract] [Full Text] [Related]

  • 5. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G, Morócz É, Korompay R, Hécz R, Bujdosó R, Puskás R, Lovas T, Gáspár E, Yahya K, Király P, Lohinai Z.
    Pathol Oncol Res; 2024 Sep; 30():1611715. PubMed ID: 38605928
    [Abstract] [Full Text] [Related]

  • 6. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 8. Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
    Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K.
    JAMA Netw Open; 2023 Dec 01; 6(12):e2347700. PubMed ID: 38100106
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X, Zhao C, Li J, Su C, Chen X, Ren S, Li X, Zhou C.
    Cancer Med; 2019 Jun 01; 8(6):2858-2866. PubMed ID: 31016879
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP, Li Q, Ma LY, Liu X, Dai M, Wang XX, Li HS, Liu JX, Shen ZH, Guo YJ, Du YX, Yang RJ, Huang YC, Zhou YC.
    Zhonghua Zhong Liu Za Zhi; 2020 Sep 23; 42(9):735-740. PubMed ID: 32988155
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Sep 23; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.